Eli Lilly Phase 3 trial of retatrutide showed average weight loss of 71.2 lbs, or about 28%, along with reduced knee pain in participants with obesity and osteoarthritis. Lilly expects seven more Phase 3 studies to conclude in 2026. Shares rose 3% in premarket trade as the company continues expanding its $1 trillion obesity-drug franchise.